Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Apr 1;65(7):548-9.
doi: 10.1016/j.biopsych.2009.01.022.

How we say no: norepinephrine, inferior frontal gyrus, and response inhibition

Gary Aston-Jones  1 , Joshua I Gold
Affiliations
Comment

How we say no: norepinephrine, inferior frontal gyrus, and response inhibition

Gary Aston-Jones et al. Biol Psychiatry. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of the race model for the stop-signal task and the effect of atomoxetine proposed in Chamberlain et al. The race model includes a GO process (green) and a STOP process (red) that are racing independently toward a common threshold. The GO stimulus onset is at time 0 (green arrow), triggering a rise in the GO process (green) after a delay. The stop stimulus onset is at 200 msec (red arrow), triggering a rise in the STOP process (red) after a delay. If the GO process reaches threshold first (upper panel), then a response is generated (non-cancelled trials). Conversely, if the STOP process finishes before the GO process (lower panel), then the response is cancelled. Functional magnetic resonance imaging studies show relatively higher activation of the right inferior frontal gyrus (RIFG) on cancelled trials. Atomoxetine decreases stop-signal reaction times and increases RIFG activation on cancelled trials, possibly by increasing the strength (rate of rise) of the Stop process. Modified with permission from Hanes et al. (6).
See this image and copyright information in PMC

Comment on

References

    1. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313–1323. - PubMed
    1. Casey BJ, Nigg JT, Durston S. New potential leads in the biology and treatment of attention deficit-hyperactivity disorder. Curr Opin Neurol. 2007;20:119–124. - PubMed
    1. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: Focus on the prefrontal cortex. Pharmacol Ther. 2007;113:523–536. - PMC - PubMed
    1. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403–450. - PubMed
    1. Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: An update. J Clin Psychopharmacol. 2008;28:S39–S45. - PubMed

MeSH terms